Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pantoprazole 20 mg/40mg for gastroesophageal reflux disease (GERD).

Trial Profile

Pantoprazole 20 mg/40mg for gastroesophageal reflux disease (GERD).

Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2014

At a glance

  • Drugs Pantoprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Acronyms PANTHER
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 17 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top